

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

Voluntary Announcement

Ascentage Pharma to Present Latest Results from Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting

Ascentage Pharma Group International (the “Company” or “Ascentage Pharma”) is pleased to announce that the latest results from three preclinical studies of the company’s novel drug candidate olverembatinib (HQP1351), MDM2-p53 inhibitor alrizomadlin (APG-115), FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, and EED inhibitor APG-5918, have been selected for presentations at the 2024 American Association of Cancer Research Annual Meeting (AACR 2024). These abstracts are now available on the AACR’s official website.

The AACR annual meeting is one of the world’s largest and longest-standing scientific gatherings in the field of cancer research. Covering some of the most cutting-edge advances in all the areas of oncology research and innovation, the annual event attracts tremendous interest from the global cancer research community. This year’s AACR annual meeting will be held from April 5, 2024 to April 10, 2024, in San Diego, California, USA.

The abstracts of the three preclinical studies from Ascentage Pharma are as follows:

Olverembatinib, a novel multikinase inhibitor, demonstrates superior antitumor activity in succinate dehydrogenase (SDH)-deficient neoplasms

- Abstract number: 1971
- Session Category: Experimental and Molecular Therapeutics
- Session Title: Kinase and Phosphatase Inhibitors 2
- Session Time:

Monday April 8, 2024, 9:00 AM – 12:30 PM, Pacific Time

Tuesday April 9, 2024, 12:00 AM – 3:30 AM, Beijing Time

Results from this preclinical study show that in SDH-deficient cancer cells, olverembatinib has superior efficacy compared to other approved tyrosine kinase inhibitors. Mechanistically, olverembatinib can exert its antitumor effects in SDH-deficient neoplasms by modulating multiple signal pathways involved in cell hypoxia, angiogenesis, proliferation, and survival. These results provide a scientific rationale for the future development of olverembatinib in SHD-deficient cancers that are presenting an urgent unmet clinical need.

Embryonic ectoderm development (EED) inhibitor APG-5918 (EEDi-5273) and MDM2 inhibitor alrizomadlin (APG-115) synergistically inhibit tumor growth in preclinical models of prostate cancer (PCa)

- Abstract number: 3223
- Session Category: Experimental and Molecular Therapeutics
- Session Title: Epigenetic Targets
- Session Time:

Monday April 8, 2024, 1:30 PM – 5:00 PM, Pacific Time

Tuesday April 9, 2024, 4:30 AM – 8:00 AM, Beijing Time

Results from this preclinical study show that in preclinical models of PCa, targeting both EED and MDM2 can synergistically enhance antitumor activities by modulating pathways related to DNA methylation, cell cycle, and apoptosis. These findings provide a scientific rationale for the future clinical development of APG-5918 combined with alrizomadlin (APG-115) for the treatment of PCa.

APG-2449, a novel focal adhesion kinase (FAK) inhibitor, inhibits metastasis and enhances the antitumor efficacy of PEGylated liposome doxorubicin (PLD) in epithelial ovarian cancer (EOC)

- Abstract number: 4569
- Session Category: Experimental and Molecular Therapeutics
- Session Title: Drug Combinations
- Session Time:

Tuesday April 9, 2024, 9:00 AM – 12:30 PM, Pacific Time

Wednesday April 10, 2024, 12:00 AM – 3:30 AM, Beijing Time

Results from this preclinical study show that the novel FAK inhibitor APG-2449 can reduce the metastasis of tumor cells and achieve synergistic antitumor effects with PLD in xenograft mouse models of ovarian cancer. These results support the future clinical development of APG-2449 combined with PLD for the treatment of ovarian cancer.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to obtain further approval for, or ultimately market, APG-115, APG-2449 and APG-5918, successfully.

By Order of the Board
Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Suzhou, People's Republic of China, March 6, 2024

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon Dazhong as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng, Mr. Ren Wei and Dr. David Sidransky as independent non-executive Directors.